Steven Keith Burke - 30 Jan 2026 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Reporting relationship: SVP, Chief Medical Officer
Issuer ticker: AKBA
Reported as of: 30 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2026, 16:41:12 UTC
Prior SEC filing: 04 Mar 2025
Next SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Carolyn M. Rucci, attorney-in-fact for Steven K. Burke

Key filing fact

Steven Keith Burke filed Form 4 for Akebia Therapeutics, Inc. (AKBA) on 03 Feb 2026.

Key facts

This page summarizes Steven Keith Burke's Form 4 filing for Akebia Therapeutics, Inc. (AKBA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2026, 16:41.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001619834 Primary reporting owner

Burke Steven Keith

Relationship: SVP, Chief Medical Officer
Address: C/O AKEBIA THERAPEUTICS, INC, 245 FIRST STREET, CAMBRIDGE
Signature: /s/ Carolyn M. Rucci, attorney-in-fact for Steven K. Burke
Signature date: 03 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKBA transaction

Common Stock

Award

Transaction value: $0
Shares: +204,000
Change %: +25%
Price: $0.000000
Shares after: 1,016,090
Date: 30 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKBA transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +320,000
Change %
Price: $0.000000
Shares after: 320,000
Date: 30 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 320,000
Exercise price: $1.41
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

Footnote F2

Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2025 and 1,500 shares of the Issuer's common stock purchased on December 31, 2025, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.

Footnote F3

The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.